Business
UPDATE: NurExone Signs Letter of Intent with Nanometrix for Its Exosome and Cargo Molecular Profiling AI-Driven Technology
Both companies will collaborate to improve NurExone's drug development stages, from R&D ...
About this update from Nurexone Biologic Inc
[{"type":"text","content":"UPDATE: NurExone Signs Letter of Intent with Nanometrix for Its Exosome and Cargo Molecular Profiling AI-Driven TechnologyBoth companies will collaborate to improve NurExone's drug development stages, from R&D to Quality AssuranceCompany to host an investor webinar on Thursday, October 20th, 2022 at 11:00 AM ESTCalgary, Alberta and Oxford, United Kingdom--(Newsfile Corp. - October 12, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the \"Company\" or \"NurExone\"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that the Company's wholly-owned subsidiary, NurExone Biologic Ltd., signed a non-binding Letter of Intent for a collaboration (the \"Collaboration\") with Nanometrix Ltd. (\"Nanometrix\"), a U.K.-based nanoparticle analysis company providing services to profile molecules of exosomes and their cargo.Under the Collaboration, NurExone's exosomes and cargo samples will be processed and analyzed by Nanometrix, which will use its proprietary Artificial Intelligence (AI) software to extract and analyze morphological and population data to achieve detailed molecular profiling of the exosomes and quantify the siRNA cargo copy number per extracellular vesicle (EV), information which was far out of reach. \"Detailed molecular profiling of our exosomes and their siRNA cargo will facilitate a quality assurance program for repeatable, mass-production of ExoTherapies towards commercialization,\" said Dr. Lior Shaltiel, CEO of NurExone. \"Nanometrix has the expertise and resources to perform this analysis in a highly professional manner and we look forward to working with them.\"\"The signing of this letter of intent is a first step towards a great milestone for Nanometrix,\" said Alexandre Kitching, CEO and Cofounder of Nanometrix. \"We are thrilled to start this collaboration with NurExone as we believe in the future of exosomes as an advanced platform for drug delivery. We look forward to deploying our technology and assisting NurExone in gaining in-depth information about their siRNA-loaded exosomes and subsequently, improving the different stages of their drug development process.\" Exosomes are best defined as EVs that have emerged as promising guided nanocarriers for drug delivery and targeted therapy, and as alternative...